OYSTER POINT PHARMA ANNOUNCES THE REMOVAL OF WILLIAM J. LINK FROM THE BOARD OF DIRECTORS
PRINCETON, NJ, March 17, 2022 – Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today hui announced that William J. Link, Ph.D., is stepping down from Oyster Point’s board of directors, effective March 17, 2022. Dr. Link will continue to act as a consultant to the company.
“On behalf of the entire Oyster Point organization, we are eternally grateful to Dr. Link for his leadership and significant contributions over the years,” said Jeffrey Nau, MMS, Ph.D., President and Chief management of Oyster Point Pharma. “Even in his retirement, he will contribute to our common goal of raising the standard of care for people suffering from ophthalmic diseases.”
Dr Link joined Oyster Point’s Board of Directors when the company was formed in July 2015 and served as a member of the Compensation Committee. He continued his service throughout the company’s successful transition from a private biopharmaceutical company to a public biopharmaceutical company, through the launch of TYRVAYA™ nasal spray (varenicline solution) and the evolution of a promising pipeline. with potentially transformative experimental therapies in a range of ocular surface diseases.
“It has been an honor to serve on Oyster Point’s Board of Trustees during this exciting time of transformation and growth,” said Dr. William J. Link. “As a shareholder and consultant, I remain a strong believer in Oyster Point’s leadership team and innovative portfolio as the company pursues its next phase of continued growth and its strategy of creating shareholder value.”
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA™ Nasal Spray (Varenicline Solution). Oyster Point has a growing pipeline of clinical and preclinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point continually strives to advance cutting-edge science and deliver therapies aimed at addressing the unmet needs of patients with ophthalmic diseases and the eye care professionals who care for them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect Oyster Point Pharma, Inc.’s current beliefs, expectations and assumptions regarding the future of the company’s business, our future plans and strategies, business opportunities, regulatory approvals, preclinical and clinical results, future financial condition and other future conditions. Words such as “may”, “will”, “expect”, “potential” or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. . These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among others: our plans and potential for success in commercializing TYRVAYA; the beneficial characteristics, safety, efficacy and therapeutic effects of TYRVAYA and our preclinical and clinical product candidates; our plans relating to the development and manufacturing of TYRVAYA and our preclinical and clinical candidates, including potential additional indications or disease areas to be evaluated and pursued; the timing of the initiation of our future preclinical studies or clinical trials; the uncertainties inherent in pharmaceutical research and development, including the likelihood of positive preclinical study results and the likelihood of clinical trials demonstrating the safety and efficacy of our products or product candidates; the timing or likelihood of regulatory filings and approvals of TYRVAYA and our clinical and preclinical candidates, including in
potential additional indications for TYRVAYA and potential filings in other jurisdictions; the prevalence of dry eye disease and neurotrophic keratopathy (NK) and the size of market opportunities for our product candidates; the potential benefits expected from strategic collaborations with third parties and our ability to attract associates with development, regulatory and commercialization expertise; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions to existing patent terms, if any; our continued reliance on third parties to conduct additional preclinical studies and clinical trials of our product candidates, and to manufacture our products and product candidates; our ability to recruit and retain key personnel necessary to develop and commercialize our products and product candidates, and to grow our business; the accuracy of our estimates regarding expenses, future revenues, capital requirements and additional funding requirements; our financial performance; market conditions; the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure needs; our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and other risks described in the “Risk Factors” section included in our public filings that we have filed and will file with the Securities and Exchange Commission (SEC).
© 2022 Oyster Point Pharma, Inc.
LifeSci Advisors, LLC